Journal
CLINICAL INFECTIOUS DISEASES
Volume 74, Issue 7, Pages 1183-1190Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciab612
Keywords
access; antibacterial; approval; commercial launch
Categories
Ask authors/readers for more resources
Limited accessibility of new antibacterials in high-income countries challenges the assumption that these countries have complete access to all medicines. This study reveals that many high-income countries have limited patient access to new antibacterials, even after regulatory approval.
Background Inaccessibility of medicines in low- and middle-income countries is a frequent challenge. Yet it is typically assumed that high-income countries have complete access to the full arsenal of medicines. This study tests this assumption for new antibacterials, which are saved as a last resort in order to prevent the development of resistance, resulting in insufficient revenues to offset costs. Prior studies report only regulatory approval, missing the important lag that occurs between approval and commercial launch, although some antibiotics never launch in some countries. Methods We identified all antibacterials approved and launched in the G7 and 7 other high-income countries in Europe for the decade beginning 1 January 2010, using quantitative methods to explore associations. Results Eighteen new antibacterials were identified. The majority were accessible in only 3 countries (United States, United Kingdom, and Sweden), with the remaining 11 high-income countries having access to less than half of them. European marketing authorization did not lead to automatic European access, as 14 of the antibacterials were approved by the European Medicines Agency but many fewer were commercially launched. There was no significant difference in access between innovative and noninnovative antibacterials. Median annual sales in the first launched market (generally the United States) for these 18 antibiotics were low, $16.2M. Conclusions Patient access to new antibacterials is limited in some high-income countries including Canada, Japan, France, Germany, Italy, and Spain. With low expected sales, companies may have decided to delay or forego commercialization due to expectations of insufficient profitability. Antibacterials approved since 2010 are not being commercially launched promptly in many high-income countries, even after regulatory approval. With low expected sales, companies may have decided to delay or forego commercialization due to expectations of insufficient profitability.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available